Skip to main content

stock

ABBV · AbbVie Inc.

What AbbVie Inc. reports to the SEC, read from its filings.

Open in the app

Price

The live ABBV price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on ABBV.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Pharmaceutical Preparations (SIC 2834)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
1,767,117,285 as of 2026-07-27 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
26.2%
Net
9.8%

Returns

ROE
—
ROA
4.7%

Health

Current ratio
0.8x
Debt/equity
—

Deep value

NCAV
—
NCAV per share
—
Price/NCAV
Locked
NNWC
—
NNWC per share
—
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profitOperating incomeNet incomeFiling
2026-06-30$16.99B—$6.43B$3.61B
10-Q filed 2026-08-03
2026-03-31$15.00B—$3.99B$695.00M
10-Q filed 2026-05-08
2025-12-31$16.62B$12.07B$4.54B$1.82B
10-K filed 2026-02-20
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2025-09-30$15.78B—$1.90B$186.00M
10-Q filed 2025-11-04
2025-06-30$15.42B—$4.89B$938.00M
10-Q filed 2026-08-03
2025-03-31$13.34B—$3.73B$1.29B
10-Q filed 2026-05-08
2024-12-31$15.10B$10.71B-$1.49B-$22.00M
10-K filed 2026-02-20
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assembled from more than one filing; the filing above is only the newest of them.
2024-09-30$14.46B—$3.83B$1.56B
10-Q filed 2025-11-04
Assets
$135.12B
Equity
-$5.93B

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31$61.16B$15.07B$4.23B$17.82B
2024-12-31$56.33B$9.14B$4.28B$17.83B
2023-12-31$54.32B$12.76B$4.86B$22.06B
2022-12-31$58.05B$18.12B$11.84B$24.25B
2021-12-31$56.20B$17.92B$11.54B$21.99B
2020-12-31$45.80B$11.36B$4.62B$16.79B
2019-12-31$33.27B$12.98B$7.88B$12.77B
2018-12-31$32.75B$6.38B$5.69B$12.79B
2017-12-31$28.22B$9.54B$5.31B$9.43B
2016-12-31$25.64B$9.34B$5.95B—

Company filings

Insiders, politicians and funds

Insider trades, last 90 days

Politician trades, last 90 days

  • Pete Sessions

    House · TX17

    Sale$15,001 to $50,000

    Fri Sep 18

  • Alan Armstrong

    Senate

    Buy$15,001 to $50,000

    Tue Jul 21

All politician trades for ABBV

Funds

News

Stories that named ABBV, and the market events around them.

Sign in to see this

Board

The ABBV board could not be loaded.

Retry the ABBV board

nakagai

Signals on ABBV come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the ABBV board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

AbbVie Inc. (ABBV): SEC filings, financials and insider trades · Nakagai